|
Demographics
|
|
Age, years, median (IQI)
|
67.7 (58.5–75.3)
|
69.0 (59.3–75.8)
|
−0.09
|
68.1 (59.5–76.6)
|
68.7 (58.1–75.5)
|
0.03
|
|
Male sex, n (%)
|
419 (65.5)
|
419 (70.8)
|
−0.11
|
425 (68.5)
|
401 (67.7)
|
0.02
|
|
Surgical status, n (%)
|
|
Nonsurgical
|
229 (36.9)
|
281 (47.5)
|
−0.22
|
261 (42.1)
|
248 (42.0)
|
−0.02
|
|
Noncardiac surgery, elective
|
37 (6.0)
|
47 (7.9)
|
−0.08
|
42 (6.7)
|
43 (7.3)
|
−0.02
|
|
Noncardiac surgery, acute
|
67 (10.8)
|
66 (11.1)
|
−0.01
|
67 (10.8)
|
65 (11.0)
|
−0.00
|
|
Cardiac surgery, elective
|
100 (16.1)
|
66 (11.1)
|
0.14
|
84 (13.5)
|
74 (12.5)
|
0.03
|
|
Cardiac surgery, acute
|
188 (30.3)
|
132 (22.3)
|
0.18
|
167 (26.8)
|
161 (27.3)
|
−0.01
|
|
SOFA score, mean (SD)
|
5.5 (2.4)
|
4.8 (2.5)
|
0.29
|
5.2 (2.5)
|
5.2 (2.5)
|
0.01
|
|
ICU treatments, n (%)
|
|
Vasopressors or inotropes
|
555 (89.4)
|
491 (82.9)
|
0.19
|
543 (87.4)
|
513 (86.6)
|
0.02
|
|
Mechanical ventilation
|
475 (76.5)
|
420 (70.9)
|
0.13
|
460 (74.0)
|
441 (74.5)
|
−0.01
|
|
Extracorporeal membrane oxygenation
|
84 (13.5)
|
40 (6.8)
|
0.23
|
67 (10.7)
|
65 (11.0)
|
−0.01
|
|
Laboratory values
|
|
Creatinine, baseline, μmol/L, median (IQI)
|
94.9 (82.0–117.0)
|
90.7 (73.7–102.2)
|
0.19
|
93.2 (76.8–115.0)
|
92.0 (76.8–111.7)
|
0.01
|
|
Potassium, mmol/L, median (IQI)
|
4.4 (3.9–5.0)
|
4.5 (4.1–5.1)
|
−0.17
|
4.4 (4.0–5.0)
|
4.5 (4.0–5.0)
|
−0.04
|
|
Sodium, mmol/L, mean (SD)
|
139.3 (7.0)
|
138.8 (7.2)
|
0.06
|
138.9 (7.1)
|
138.8 (7.0)
|
0.00
|
|
Preadmission morbidity, n (%)
|
|
Renal disease
|
178 (28.7)
|
208 (35.1)
|
−0.14
|
198 (31.9)
|
188 (31.8)
|
0.00
|
|
Diabetes
|
101 (16.3)
|
107 (18.1)
|
−0.05
|
108 (17.4)
|
104 (17.5)
|
−0.00
|
|
Congestive heart disease
|
180 (29.0)
|
120 (20.3)
|
0.20
|
161 (25.9)
|
153 (25.9)
|
−0.00
|
|
Myocardial infarction
|
154 (24.8)
|
136 (23.0)
|
0.04
|
149 (24.0)
|
148 (25.0)
|
−0.02
|
|
Cerebrovascular disease
|
80 (12.9)
|
86 (14.5)
|
−0.05
|
83 (13.3)
|
76 (12.9)
|
0.01
|
|
Chronic pulmonary disease
|
113 (18.2)
|
90 (15.2)
|
0.08
|
101 (16.3)
|
92 (15.6)
|
0.02
|
|
Liver disease
|
21 (3.4)
|
23 (3.9)
|
−0.03
|
22 (3.6)
|
21 (3.5)
|
0.00
|
|
Vascular disease
|
172 (27.7)
|
161 (27.2)
|
0.01
|
180 (29.1)
|
164 (27.7)
|
0.03
|
|
Tumor
|
68 (11.0)
|
95 (16.0)
|
−0.15
|
85 (13.7)
|
81 (13.7)
|
−0.00
|
|
Lymphoma
|
9 (1.4)
|
6 (1.0)
|
0.04
|
8 (1.3)
|
9 (1.5)
|
−0.01
|
|
Leukemia
|
7 (1.1)
|
5 (0.8)
|
0.03
|
6 (0.9)
|
7 (1.1)
|
−0.02
|
|
Metastasis
|
16 (2.6)
|
17 (2.9)
|
−0.02
|
16 (2.5)
|
17 (2.9)
|
−0.03
|
|
Year of treatment, n (%)
|
|
2005–2006
|
95 (15.3)
|
149 (25.2)
|
−0.25
|
121 (19.5)
|
115 (19.4)
|
−0.04
|
|
2007–2008
|
101 (16.3)
|
120 (20.3)
|
−0.10
|
112 (18.0)
|
106 (18.0)
|
−0.00
|
|
2009–2010
|
141 (22.7)
|
93 (15.7)
|
0.18
|
119 (19.1)
|
119 (20.1)
|
−0.03
|
|
2011–2012
|
158 (25.4)
|
94 (15.9)
|
0.24
|
132 (21.3)
|
124 (20.9)
|
0.01
|
|
2013–2014
|
126 (20.3)
|
136 (23.0)
|
−0.07
|
138 (22.1)
|
128 (21.7)
|
0.01
|
